Anticancer Therapies – News and Features

Monash University-led research reveals the crystal structure of LAG-3 binding to HLA-II molecules, a breakthrough in cancer immunotherapy. This study provides a foundation for developing targeted therapies to block LAG-3 activity.

The complex interactions of the tumor–immune–gut axis can shape responses to immunotherapy in ovarian cancer, emphasizing the importance of understanding the patient's microbiome.

New research shows that glioblastoma has an internal clock and syncs its daily rhythms to match — and take advantage of — the rhythms of its host.

The delicate balance between immune system rest and activation is crucial for our health. For T cells, this balance is controlled by a single protein.

Two bacterial strains may be linked to higher rates of colon cancer in some countries. This may provide a target for the development of measures such as vaccines to cut rates of colon cancer.

A groundbreaking new database could lead to vast improvements in precision oncology by documenting sex-based differences in cancer treatment efficacy, biomarkers, risk factors, and microbial influences across 71 cancer types.

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how they are being addressed.

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, researchers showed.

Researchers used glioblastoma-derived organoids to predict patient responses to CAR T cell therapy with remarkable accuracy. These organoids mirrored the tumor’s reaction to treatment in real time, offering insights into efficacy and neurotoxicity.

A UT Southwestern trial found selinexor, an FDA-approved drug, effective in KRAS-mutated non-small cell lung cancer (NSCLC). Combined with chemotherapy, it achieved tumor control in 80% of cases.